Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man Max 99 years
Sanofi-Aventis (Finland)
Update Il y a 4 ans
INITIATE (INITiate Insulin by Aggressive Titration and Education): a randomised study to compare initiation of insulin combination therapy in type two diabetic patients individually and in groups
Not provided at time of registration
Country
Finland
,
Netherlands
,
Sweden
,
United Kingdom
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-aventis
Update Il y a 4 ans
A multicenter clinical trial to evaluate quality of life in patients with Type 2 diabetes before and after changing therapy to a combination of insulin glargine and oral antidiabetic drugs in a real life situation
To assess QoL changes and treatment satisfaction in a real life situation in patients with Type 2 diabetes inadequately controlled on a combination of OAD + NPH insulin treatment that are switched to ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
Estudio randomizado de fase II de Docetaxel en combinación con Oxaliplatino con o sin 5-FU o Capecitabina, en cáncer gástrico metastásico o en recurrencia local que no haya sido tratado previamente para la enfermedad avanzada con quimioterapia
Evaluar el tiempo hasta la progresión (TTP) de docetaxel en combinación con oxaliplatino con o sin 5-FU o capecitabina en cáncer gástrico metastásico o con recurrencia local que no ha sido tratado pre...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine (REPEVAX) administered concomitantly versus non-concomitantly with an influenza vaccine (VAXIGRIP) to subjects of 60 years of age and older
- To demonstrate that REPEVAX administered concomitantly with VAXIGRIP in subjects 60 years of age and older is at least as immunogenic as REPEVAX administered alone and - To demonstrate that VAXIGRIP...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
SANOFI AVENTIS DOCOX_C_00082 : Essai de phase 2 randomisé évaluant un traitement par docétaxel et oxaliplatine associé ou non au 5-FU ou à la capécitabine, chez des patients ayant un cancer gastrique métastatique ou en récidive locale. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité d’une chimiothérapie par docétaxel et oxaliplatine associée soit au 5-FU, soit à la capécitabine, chez des patients ayant un cancer gastrique métasta...
Country
France
organs
Estomac
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Étude ACT15377 : étude de phase 1-2, évaluant la tolérance, l’efficacité préliminaire et la pharmacocinétique de l’isatuximab seul ou associé à l’atézolizumab, chez des patients ayant des tumeurs malignes avancées.
Le carcinome hépatocellulaire (CHC) est un cancer primitif du foie qui se développe, dans la grande majorité des cas, à partir des cellules du foie déjà endommagées par une maladie chronique ou une ci...
Country
France
organs
Tête et cou
,
Ovaire
,
Cerveau
,
Primitif du foie
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman Max 99 years
Support from Sanofi-Aventis, Roche Pharma and Pfizer
Update Il y a 4 ans
A randomised phase II study of cytotoxic chemotherapy or cytotoxic chemotherapy combined with celecoxib or trastuzumab as primary chemotherapy for patients with high risk localised breast cancer not amenable to breast conserving therapy
Not provided at time of registration
Country
France
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route)
In each group: 1) To evaluate compliance, in terms of immunogenicity, of the corresponding strength of the ID influenza vaccine NH 2010-2011 formulation with the requirements of the Committee for Prop...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur Inc
Update Il y a 4 ans
Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses Of BIKEN Acellular Pertussis Vaccine in Combination with Diphtheria and Tetanus Toxoids (Tripedia®) Or Who Have Received Primary Vaccination with 3 Doses of Whole-Cell Pertussis Vaccine, Plus At Least 1 Pertussis Booster Vaccination
To describe and characterize adverse events occurring after vaccination with COVAXiS or REPEVAX vaccine among two groups: Group 1 - adolescents 10-14 years of age who participated in study 371-03/01 ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Aventis AG
Update Il y a 4 ans
Study in Subjects with Asthma to Compare the Bronchodilatoric Effects of Salmeterol (at two different doses) and Fluticasone Propionate when Taken Via a Novel Inhaler Device (PulmoJet®) Compared to the Seretide Diskus® Inhaler
The primary objective is to demonstrate the therapeutic non-inferiority of the bronchodilator responses (area under the time curve of forced expiratory volume in 1 second [AUC-FEV1]) over 12 hours of...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next